Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Binding Inhibition Assay from US Patent US9533985: "Sulfonamide derivative and medicinal use thereof"
Assay data:103 Active, 1 Activity ≤ 1 nM, 104 Activity ≤ 1 µM, 104 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Assay data:40 Active, 30 Activity ≤ 1 nM, 40 Activity ≤ 1 µM, 40 Tested
Assay data:40 Active, 37 Activity ≤ 1 µM, 40 Tested
Competitive Cell Adhesion Assay from Article 10.1021/jm070790o: "Highly Potent, Water Soluble Benzimidazole Antagonist for Activated alpha(4)beta(1) Integrin."
Assay data:10 Active, 2 Activity ≤ 1 nM, 10 Activity ≤ 1 µM, 10 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Specificity of Inhibitors on Cell Adhesion Assay from Article 10.1021/jm070252b: "Small molecule inhibitors of integrin alpha2beta1."
Assay data:5 Active, 2 Activity ≤ 1 µM, 5 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
VLA-4/VCAM-1 binding assay from Article 10.1016/j.bmc.2005.11.058: "Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists."
Assay data:24 Active, 4 Activity ≤ 1 nM, 24 Activity ≤ 1 µM, 24 Tested
VLA-4/VCAM-1 binding assay from Article 10.1016/j.bmc.2006.12.006: "Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists."
Assay data:18 Active, 3 Activity ≤ 1 nM, 18 Activity ≤ 1 µM, 18 Tested
K562 Cell Adhesion Assay (alpha4beta7 Mediated Adhesion/MAdCAM-1) from Article 10.1016/j.bmc.2006.01.067: "Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent."
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
Ramos Cell Adhesion Assay (alpha4beta1 Mediated Adhesion/VCAM-1) from Article 10.1016/j.bmc.2006.01.067: "Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent."
Cell Adhesion Assay (alpha4beta1 Mediated Adhesion/VCAM-1) from Article 10.1016/j.bmcl.2006.09.069: "2,6-Quinolinyl derivatives as potent VLA-4 antagonists."
Assay data:22 Active, 21 Activity ≤ 1 µM, 22 Tested
Jurkat J6 Scintillation Proximity Assay from Article 10.1016/j.bmcl.2006.01.025: "Pyridone derivatives as potent and selective VLA-4 integrin antagonists."
Assay data:11 Active, 2 Activity ≤ 1 nM, 14 Activity ≤ 1 µM, 15 Tested
Jurkat J6 Scintillation Proximity Assay from Article 10.1016/j.bmcl.2006.08.044: "Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists."
Assay data:29 Active, 7 Activity ≤ 1 nM, 29 Activity ≤ 1 µM, 29 Tested
Jurkat Cell Adhesion Inhibition Assay from Article 10.1002/bip.20588: "Structure-activity relationship studies of a series of peptidomimetic ligands for alpha(4) beta(1) integrin on Jurkat T-leukemia cells."
Assay data:51 Active, 1 Activity ≤ 1 nM, 46 Activity ≤ 1 µM, 51 Tested
Ramos Cell Adhesion Assay (alpha4beta1 Mediated Adhesion/VCAM-1) from Article 10.1016/j.bmc.2005.07.022: "Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists."
Assay data:37 Active, 2 Activity ≤ 1 nM, 37 Activity ≤ 1 µM, 37 Tested
Ramos Cell Adhesion Assay (alpha4beta1 Mediated Adhesion/VCAM-1) from Article 10.1021/jm060031q: "Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists."
Assay data:30 Active, 29 Activity ≤ 1 µM, 30 Tested
ELISA assay from US Patent US9610264: "Compounds for the treatment and prevention of retroviral infections"
Assay data:15 Active, 6 Activity ≤ 1 nM, 15 Activity ≤ 1 µM, 15 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Displacement of 125I-VCAM-Ig from VLA4 in human Jurkat cells incubated for 30 mins by scintillation counting method
Assay data:4 Active, 4 Activity ≤ 1 nM, 4 Activity ≤ 1 µM, 4 Tested
Inhibition of alpha4beta1 integrin (unknown origin) by solid phase binding assay
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
Antagonist activity at alpha4beta1 in human Jurkat E6.1 cells assessed as reduction in exposure of HUTS-21 epitope measured by mAb binding
Assay data:2 Tested
SummaryPubMed CitationRelated BioAssays by Target
Agonist activity at alpha4beta1 in human Jurkat E6.1 cells assessed as increase in HUTS-21 antibody binding by flow cytometry analysis
Assay data:1 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on